Exact Sciences price target raised to $70 from $60 at Piper Sandler

Piper Sandler raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Overweight rating on the shares. The firm thinks Exact Sciences presents a compelling investment opportunity underpinned by the Cologuard franchise and expanding opportunities in Cancerguard and MRD long term. The company can drive volumes through its new first-line screening strategy, Cares Gap, and Rescreens, Piper adds. This is all validated by the recent NCI study.